Announced
Synopsis
Pfizer, a biopharmaceutical company, agreed to invest $185m in BioNTech, a manufacturer of active immunotherapies. “We have already started working with Pfizer on our COVID-19 vaccine and are pleased to announce these further details of our ongoing collaboration, which reflects both companies’ strong commitment to move quickly to bring a safe and efficacious vaccine to patients worldwide,” Ugur Sahin, BioNTech Co-Founder and CEO.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Seller Team (3)
Bidder Team (9)
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
All rights reserved. Copyright © 2025 Datasite